Abstract
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A2 and the release of arachidonic acid (AA) from membrane phospholipids. The AA is subsequently transformed by cyclooxygenase (COX) and lipoxygenase (LO) pathways to prostaglandins, thromboxane and leukotrienes collectively termed eicosanoids. Eicosanoid production is considerably increased during inflammation. Both COX and LO pathways are of particular clinical relevance. The COX pathway is the major target for non-steroidal anti-inflammatory drugs (NSAIDs), the most popular medications used to treat pain, fever and inflammation. Although their anti-inflammatory effects are well known, their long-term use is associated with gastrointestinal (GI) complications such as ulceration. In 1991, it was discovered that COX exists in two distinct isozymes, COX-1 and COX-2, of which COX-2 is primarily expressed at sites of inflammation and produces pro-inflammatory eicosanoids. For this reason, COX-2 selective inhibitors (COXIBs) have been developed recently as anti-inflammatory agents to minimize the risk of GI toxicity. Recently, some COX-2 selective inhibitors have shown adverse cardiovascular side effects, resulting in the withdrawal of rofecoxib and valdecoxib from the market. Selective inhibition of COX-2 without reducing COX-1-mediated thromboxane production could alter the balance between prostacyclin and thromboxane and promote a prothrombotic state, thereby explaining the observed COX- 2 cardiovascular risk. In this review, we describe mechanisms for the production of pro-inflammatory eicosanoid mediators contributing to inflammation and summarize promising options for the prevention of inflammatory mediator formation and the therapeutic inhibition of pain and inflammation.
Keywords: Arachidonic Acid Metabolism, Lipoxin, Eosinophils, Leukotriene B4 Receptors, ysteinyl-leukotrienes receptors, Inflammation, Fever, Lung Diseases
Current Topics in Medicinal Chemistry
Title: Eicosanoids in Inflammation: Biosynthesis, Pharmacology, and Therapeutic Frontiers
Volume: 7 Issue: 3
Author(s): Subhash P. Khanapure, David S. Garvey, David R. Janero and L. Gordon Letts
Affiliation:
Keywords: Arachidonic Acid Metabolism, Lipoxin, Eosinophils, Leukotriene B4 Receptors, ysteinyl-leukotrienes receptors, Inflammation, Fever, Lung Diseases
Abstract: In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A2 and the release of arachidonic acid (AA) from membrane phospholipids. The AA is subsequently transformed by cyclooxygenase (COX) and lipoxygenase (LO) pathways to prostaglandins, thromboxane and leukotrienes collectively termed eicosanoids. Eicosanoid production is considerably increased during inflammation. Both COX and LO pathways are of particular clinical relevance. The COX pathway is the major target for non-steroidal anti-inflammatory drugs (NSAIDs), the most popular medications used to treat pain, fever and inflammation. Although their anti-inflammatory effects are well known, their long-term use is associated with gastrointestinal (GI) complications such as ulceration. In 1991, it was discovered that COX exists in two distinct isozymes, COX-1 and COX-2, of which COX-2 is primarily expressed at sites of inflammation and produces pro-inflammatory eicosanoids. For this reason, COX-2 selective inhibitors (COXIBs) have been developed recently as anti-inflammatory agents to minimize the risk of GI toxicity. Recently, some COX-2 selective inhibitors have shown adverse cardiovascular side effects, resulting in the withdrawal of rofecoxib and valdecoxib from the market. Selective inhibition of COX-2 without reducing COX-1-mediated thromboxane production could alter the balance between prostacyclin and thromboxane and promote a prothrombotic state, thereby explaining the observed COX- 2 cardiovascular risk. In this review, we describe mechanisms for the production of pro-inflammatory eicosanoid mediators contributing to inflammation and summarize promising options for the prevention of inflammatory mediator formation and the therapeutic inhibition of pain and inflammation.
Export Options
About this article
Cite this article as:
Khanapure P. Subhash, Garvey S. David, Janero R. David and Gordon Letts L., Eicosanoids in Inflammation: Biosynthesis, Pharmacology, and Therapeutic Frontiers, Current Topics in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/156802607779941314
DOI https://dx.doi.org/10.2174/156802607779941314 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Explorations on Marine-derived Fungi for L-Asparaginase – Enzyme with Anticancer Potentials
Current Chemical Biology Epicardial Adipose Tissue: Another Tassel in the Complex Fabric of Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Non-Peptidic Small-Molecule Antagonists of the Human Platelet Thrombin Receptor PAR-1
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Genetic Polymorphisms in UDP-Glucuronosyltransferase 1A6 Are Not Associated with NSAIDs-Related Peptic Ulcer Haemorrhage
Drug Metabolism Letters Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials
Mini-Reviews in Medicinal Chemistry Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Peroxisome Proliferator-activated Receptor-γ As A Novel and Promising Target For Treating Cancer <i>Via</i> Regulation of Inflammation: A Brief Review
Mini-Reviews in Medicinal Chemistry Evaluation of Glutathione Bioactivity on <i>Toxoplasma Gondii</i> in BALB/c Mice Post Impact of Selenium and Calcium Supplementation
Infectious Disorders - Drug Targets Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments
Current Medicinal Chemistry Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Dihydropyrimidinones Scaffold as a Promising Nucleus for Synthetic Profile and Various Therapeutic Targets: A Review
Current Organic Synthesis An Overview of Novel Coronavirus Disease 2019: A Global Havoc
Coronaviruses Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity
Current Stem Cell Research & Therapy Cancer-Related Fatigue: Still an Enigma to be Solved Quickly
Reviews on Recent Clinical Trials Editorial [Hot Topic: Toll-Like Receptors and Innate Immunity: Potential Drug Targets for Treatment of Infectious, Inflammatory, and Autoimmune Diseases (Executive Editor: Emilio Jirillo)]
Current Pharmaceutical Design Pathogenesis and Clinical Features of Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology 6-Aryl-4-Oxohexanoic Acids: Synthesis, Effects on Eicosanoid Biosynthesis,and Anti-Inflammatory In Vivo-Activities
Medicinal Chemistry Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Synthesis and Characterization of Water-soluble Conjugates of Cabazitaxel Hemiesters-Dextran
Anti-Cancer Agents in Medicinal Chemistry